First-in-human HIV-remission studies: reducing and justifying risk.
about
'Well, It's the Risk of the Unknown… Right?': A Qualitative Study of Perceived Risks and Benefits of HIV Cure Research in the United States."We Need to Deploy Them Very Thoughtfully and Carefully": Perceptions of Analytical Treatment Interruptions in HIV Cure Research in the United States-A Qualitative Inquiry.Perceptions of Equipoise, Risk-Benefit Ratios, and "Otherwise Healthy Volunteers" in the Context of Early-Phase HIV Cure Research in the United States: A Qualitative Inquiry.Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations.Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment.Ethical issues in HIV remission trials
P2860
First-in-human HIV-remission studies: reducing and justifying risk.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
First-in-human HIV-remission studies: reducing and justifying risk.
@en
type
label
First-in-human HIV-remission studies: reducing and justifying risk.
@en
prefLabel
First-in-human HIV-remission studies: reducing and justifying risk.
@en
P2860
P1476
First-in-human HIV-remission studies: reducing and justifying risk.
@en
P2093
Rebecca Dresser
P2860
P356
10.1136/MEDETHICS-2015-103115
P577
2016-05-03T00:00:00Z